Table 1.

Efficacy and safety of convalescent plasma transfusion as a treatment for COVID-19 patients.

Author	No. of patients	Efficacy	Safety
Abolghasemi	189	No differences in mortality. Lower length of hospitalization and higher discharges.	No adverse events
Cheng	80	Better clinical outcomes with early plasma administration	No adverse reactions
Gharbharan*	86	No improvement in mortality, hospital stay, or day-15 disease severity	No serious adverse events
Joyner	21987	Decrease in mortality rate	Adverse events in less than 1% (transfusion reactions, thrombotic events, cardiac events).
Li*	103	No improvement in clinical within 28 days	2 patients had an adverse event after transfusion that improved with supportive therapy
Xia	138	Symptoms improvement and lower mortality rate	No serious adverse events

*Randomized clinical trials. Dpt, Days post-transfusion.